Effects of diquafosol tetrasodium administration on visual function in short break-up time dry eye

Minako Kaido, Miki Uchino, Takashi Kojima, Murat Dogru, Kazuo Tsubota

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

Purpose: To investigate the effect of diquafosol tetrasodium on tear and visual function in short break-up time (sBUT) dry eye (DE). Methods: This interventional nonrandomized comparative study involved 11 eyes in 11 patients with sBUT DE (symptom-positive sBUT group) and 13 eyes in 13 volunteers with BUT values≤5 s without DE symptoms (symptom-negative sBUT group). Tear function was assessed by measuring BUT and Schirmer values. Serial measurements were made of visual acuities (using a functional visual acuity measurement system) and higher-order aberrations (using a wavefront sensor). The parameters were compared before and 1 month after diquafosol tetrasodium instillation. Any changes in symptomatology after administration were also recorded. Results: After diquafosol tetrasodium administration, BUT values tended to increase in the symptom-positive sBUT group (P=0.07) and significantly increased in the symptom-negative sBUT group (P<0.05). LogMAR functional, minimal, and maximal visual acuities and higher-order aberrations significantly decreased after diquafosol tetrasodium administration in the symptom-positive sBUT group (P<0.05), while there were no significant changes in these values in the symptom-negative sBUT group (P>0.05). Diquafosol tetrasodium administration provided relief of DE symptoms in 75% of patients in the symptom-positive sBUT group. Conclusions: Diquafosol tetrasodium appeared to improve tear film stability and visual function in sBUT DE.

Original languageEnglish
Pages (from-to)595-603
Number of pages9
JournalJournal of Ocular Pharmacology and Therapeutics
Volume29
Issue number6
DOIs
Publication statusPublished - 2013 Jul 1

Fingerprint

Tears
Visual Acuity
diquafosol
Volunteers

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Ophthalmology
  • Pharmacology

Cite this

Effects of diquafosol tetrasodium administration on visual function in short break-up time dry eye. / Kaido, Minako; Uchino, Miki; Kojima, Takashi; Dogru, Murat; Tsubota, Kazuo.

In: Journal of Ocular Pharmacology and Therapeutics, Vol. 29, No. 6, 01.07.2013, p. 595-603.

Research output: Contribution to journalArticle

Kaido, Minako ; Uchino, Miki ; Kojima, Takashi ; Dogru, Murat ; Tsubota, Kazuo. / Effects of diquafosol tetrasodium administration on visual function in short break-up time dry eye. In: Journal of Ocular Pharmacology and Therapeutics. 2013 ; Vol. 29, No. 6. pp. 595-603.
@article{7378bf8403a74eedb848c5501efa8411,
title = "Effects of diquafosol tetrasodium administration on visual function in short break-up time dry eye",
abstract = "Purpose: To investigate the effect of diquafosol tetrasodium on tear and visual function in short break-up time (sBUT) dry eye (DE). Methods: This interventional nonrandomized comparative study involved 11 eyes in 11 patients with sBUT DE (symptom-positive sBUT group) and 13 eyes in 13 volunteers with BUT values≤5 s without DE symptoms (symptom-negative sBUT group). Tear function was assessed by measuring BUT and Schirmer values. Serial measurements were made of visual acuities (using a functional visual acuity measurement system) and higher-order aberrations (using a wavefront sensor). The parameters were compared before and 1 month after diquafosol tetrasodium instillation. Any changes in symptomatology after administration were also recorded. Results: After diquafosol tetrasodium administration, BUT values tended to increase in the symptom-positive sBUT group (P=0.07) and significantly increased in the symptom-negative sBUT group (P<0.05). LogMAR functional, minimal, and maximal visual acuities and higher-order aberrations significantly decreased after diquafosol tetrasodium administration in the symptom-positive sBUT group (P<0.05), while there were no significant changes in these values in the symptom-negative sBUT group (P>0.05). Diquafosol tetrasodium administration provided relief of DE symptoms in 75{\%} of patients in the symptom-positive sBUT group. Conclusions: Diquafosol tetrasodium appeared to improve tear film stability and visual function in sBUT DE.",
author = "Minako Kaido and Miki Uchino and Takashi Kojima and Murat Dogru and Kazuo Tsubota",
year = "2013",
month = "7",
day = "1",
doi = "10.1089/jop.2012.0246",
language = "English",
volume = "29",
pages = "595--603",
journal = "Journal of Ocular Pharmacology and Therapeutics",
issn = "1080-7683",
publisher = "Mary Ann Liebert Inc.",
number = "6",

}

TY - JOUR

T1 - Effects of diquafosol tetrasodium administration on visual function in short break-up time dry eye

AU - Kaido, Minako

AU - Uchino, Miki

AU - Kojima, Takashi

AU - Dogru, Murat

AU - Tsubota, Kazuo

PY - 2013/7/1

Y1 - 2013/7/1

N2 - Purpose: To investigate the effect of diquafosol tetrasodium on tear and visual function in short break-up time (sBUT) dry eye (DE). Methods: This interventional nonrandomized comparative study involved 11 eyes in 11 patients with sBUT DE (symptom-positive sBUT group) and 13 eyes in 13 volunteers with BUT values≤5 s without DE symptoms (symptom-negative sBUT group). Tear function was assessed by measuring BUT and Schirmer values. Serial measurements were made of visual acuities (using a functional visual acuity measurement system) and higher-order aberrations (using a wavefront sensor). The parameters were compared before and 1 month after diquafosol tetrasodium instillation. Any changes in symptomatology after administration were also recorded. Results: After diquafosol tetrasodium administration, BUT values tended to increase in the symptom-positive sBUT group (P=0.07) and significantly increased in the symptom-negative sBUT group (P<0.05). LogMAR functional, minimal, and maximal visual acuities and higher-order aberrations significantly decreased after diquafosol tetrasodium administration in the symptom-positive sBUT group (P<0.05), while there were no significant changes in these values in the symptom-negative sBUT group (P>0.05). Diquafosol tetrasodium administration provided relief of DE symptoms in 75% of patients in the symptom-positive sBUT group. Conclusions: Diquafosol tetrasodium appeared to improve tear film stability and visual function in sBUT DE.

AB - Purpose: To investigate the effect of diquafosol tetrasodium on tear and visual function in short break-up time (sBUT) dry eye (DE). Methods: This interventional nonrandomized comparative study involved 11 eyes in 11 patients with sBUT DE (symptom-positive sBUT group) and 13 eyes in 13 volunteers with BUT values≤5 s without DE symptoms (symptom-negative sBUT group). Tear function was assessed by measuring BUT and Schirmer values. Serial measurements were made of visual acuities (using a functional visual acuity measurement system) and higher-order aberrations (using a wavefront sensor). The parameters were compared before and 1 month after diquafosol tetrasodium instillation. Any changes in symptomatology after administration were also recorded. Results: After diquafosol tetrasodium administration, BUT values tended to increase in the symptom-positive sBUT group (P=0.07) and significantly increased in the symptom-negative sBUT group (P<0.05). LogMAR functional, minimal, and maximal visual acuities and higher-order aberrations significantly decreased after diquafosol tetrasodium administration in the symptom-positive sBUT group (P<0.05), while there were no significant changes in these values in the symptom-negative sBUT group (P>0.05). Diquafosol tetrasodium administration provided relief of DE symptoms in 75% of patients in the symptom-positive sBUT group. Conclusions: Diquafosol tetrasodium appeared to improve tear film stability and visual function in sBUT DE.

UR - http://www.scopus.com/inward/record.url?scp=84880199833&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84880199833&partnerID=8YFLogxK

U2 - 10.1089/jop.2012.0246

DO - 10.1089/jop.2012.0246

M3 - Article

C2 - 23537148

AN - SCOPUS:84880199833

VL - 29

SP - 595

EP - 603

JO - Journal of Ocular Pharmacology and Therapeutics

JF - Journal of Ocular Pharmacology and Therapeutics

SN - 1080-7683

IS - 6

ER -